PDCD1 and hyperinsulinemic hypoglycemia, familial, 4: Pembrolizumab, a highly selective IgG4-kappa humanized monoclonal antibody targeting PD-1, is indicated for the management of patients with advanced microsatellite instability-high or mismatch repair deficiency, and PD-L1-positive expression is associated with improved survival [12, 17].